UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln
April 14, 2015 at 18:23 PM EDT
April 14 (Reuters) - Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion.